Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Geron Corp. (NASDAQ: GERN).

Full DD Report for GERN

You must become a subscriber to view this report.


Recent News from (NASDAQ: GERN)

Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that results from IMbark, a Phase 2 clini...
Source: GlobeNewswire
Date: December, 03 2018 16:22
Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS), were presented at the 60th Americ...
Source: GlobeNewswire
Date: December, 03 2018 06:00
Geron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present a company overview at the following investor conferences: Stifel 2018 Healthcare Conference ...
Source: GlobeNewswire
Date: November, 07 2018 16:30
Today's Research Reports on Trending Tickers: bluebird bio and Geron
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow Jones Industrial Average gained 0.76 percent to close at 25,461.70, while the S&P 50...
Source: ACCESSWIRE IA
Date: November, 06 2018 07:55
Geron's Last Hurrah?
I have vacillated in titling this article. I started to write it in the glow of the 11/1/18 ASH news run-up (release of ASH presentation transcripts) in stock price. As I started to write this posting on 11/1/18, I tentatively titled it: "Geron, The Comeback Kid?". After I listened to Geron's ...
Source: SeekingAlpha
Date: November, 05 2018 07:53
Cancer Research Highlight: Geron Looks To Get Digging Out Of 2018
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Much ink has been spilled ab...
Source: SeekingAlpha
Date: November, 02 2018 08:00
Geron's (GERN) CEO Dr. John Scarlett on Q3 2018 Results - Earnings Call Transcript
Geron Corporation (NASDAQ:GERN) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Suzanne Messere - Investor Relations Dr. John Scarlett - President and CEO Olivia Bloom - Chief Financial Officer Analysts George Zavoico - B. Riley FBR Presentation...
Source: SeekingAlpha
Date: November, 01 2018 21:14
Geron Q3 cash balance up 75%
Geron (NASDAQ: GERN ) Q3 results ($M): Revenue: 0.2 (+1.2%). More news on: Geron Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 16:13
Geron beats by $0.02, misses on revenue
Geron (NASDAQ: GERN ): Q3 GAAP EPS of -$0.03 beats by $0.02 . Revenue of $0.17M (+6.3% Y/Y) misses by $0.04M . Cash and equivalents $184.8M. Press Release More news on: Geron Corporation, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 01 2018 16:08
Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December Conference call scheduled for 4:30 p.m. ET today MENLO PARK,...
Source: GlobeNewswire
Date: November, 01 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.361.351.421.352,258,935
2018-12-131.431.391.481.396,915,396
2018-12-121.411.4531.471.372,313,335
2018-12-111.441.3951.461.352,191,412
2018-12-101.511.391.541.354,958,511

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14320,216807,17439.6712Short
2018-12-13366,5375,389,2306.8013Cover
2018-12-12339,310789,54842.9752Short
2018-12-11381,610796,25947.9254Short
2018-12-10867,9951,593,36154.4757Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GERN.


About Geron Corp. (NASDAQ: GERN)

Logo for Geron Corp. (NASDAQ: GERN)

Not available

 

Contact Information

 

 

Current Management

  • Ronald W. Eastman / President, CEO
  • David L. Greenwood / CFO, Secretary

Current Share Structure

  • Market Cap: $528,551,749 - 05/16/2018
  • Issue and Outstanding: 160,654,027 - 03/07/2018

 


Recent Filings from (NASDAQ: GERN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 02 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018

 

 


Daily Technical Chart for (NASDAQ: GERN)

Daily Technical Chart for (NASDAQ: GERN)


Stay tuned for daily updates and more on (NASDAQ: GERN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GERN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GERN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GERN and does not buy, sell, or trade any shares of GERN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/